Pardeep Heir

Associate Norton Rose Fulbright Canada LLP
Pardeep Heir

Pardeep Heir

Biography

Pardeep Heir, Ph.D., practises intellectual property law with a focus on patent litigation.

Pardeep has experience working on a wide range of patent litigation mandates, including patent infringement, patent impeachment, and damages actions under the Patent Act and Patented Medicines (Notice of Compliance) Regulations. Leveraging over a decade of scientific research experience, Pardeep has represented clients in patent disputes related to a range of biotechnology and pharmaceutical products, including small molecules, recombinant proteins, monoclonal antibodies and gene therapy vectors.

In his pharmaceutical regulatory practice, Pardeep advises on patent listing and pricing issues. He completed a secondment at a leading multinational pharmaceutical company where he gained valuable experience with a broad range of legal matters.

Before his legal career, Pardeep worked as a scientific associate at a cancer research centre. His research has been published in peer-reviewed scientific journals and presented at international scientific conferences.

Professional experience

Rankings and recognitions

Rankings and recognitions

  • Canadian Law Awards 2022, Commercial Litigation Case of the Year Excellence Awardee for Pharmascience Inc. v. Pfizer Canada ULC

Education

Education

  • J.D., University of Toronto, 2019
  • Ph.D., University of Toronto, 2015
  • B.Sc. (Hons.), York University, 2008

Admissions

Admissions

  • Ontario 2020

Publications

Publications

  • Co-author, "c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein," Molecular Cancer Research, 2020
  • Co-author, "CIC protein instability contributes to tumorigenesis in glioblastoma," Nature Communications, 2019
  • First author, "Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling," The Journal of Biological Chemistry, 2016
  • First author, "Hydroxylation-Dependent Interaction of Substrates to the Von Hippel-Lindau Tumor Suppressor Protein (VHL)," Methods in Molecular Biology, 2016
  • Co-author, "Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis," Nature Communications, 2015
  • Co-author, "Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway," Oncogene, 2015
  • Co-author, "Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation," Proceedings of the National Academy of Sciences of the United States of America, 2014
  • First author, "DCNL1 functions as a substrate sensor and activator of cullin 2-RING ligase," Molecular and Cellular Biology, 2013
  • Co-author, "Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1," Proceedings of the National Academy of Sciences of the United States of America, 2012
  • Co-author, "Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia," Nature Medicine, 2011

Memberships and activities

Memberships and activities

  • Canadian Bar Association – Patents and Industrial Design Committee
  • Ontario Bar Association
  • Toronto Intellectual Property Group
  • Intellectual Property Institute of Canada

Insights and news